Calliditas: An approval in China during 2023 is now more likely - Redeye
Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest Medical has announced that the Center for Drug Evaluation in China has recommended a Priority Review for Nefecon.
ANNONS
Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest Medical has announced that the Center for Drug Evaluation in China has recommended a Priority Review for Nefecon.
